Quantcast

Allergan's Vraylar Gets FDA Nod for Maintenance Therapy


Shutterstock photo

Allergan plc AGN announced that the FDA has approved its supplemental New Drug Application (sNDA) for label expansion of its schizophrenia capsule, Vraylar (cariprazine), for maintenance treatment.

Notably, Vraylar is already approved in the United States for acute treatment of schizophrenia and bipolar disorder. It is also approved in Europe for the given indication.

Shares of Allergan have declined 16.9% this year so far, comparing favorably with the  industry 's decrease of 31.5%.

The FDA approval was based on new data from a 72-week study in the prevention of relapse in adult patients with schizophrenia. Data from the study demonstrated that long-term treatment with Vraylar delayed time to relapse compared with placebo over the course of up to 72 Weeks.

Significantly, Vraylar has performed above expectations in 2016, recording sales of $94.3 million in the year. The drug is likely to be a key driver of Allergan's top-line growth in 2017.

Per the company's press release, approximately 2.4 million people are affected by schizophrenia in the United States. Also, the disease relapses in 60-70% patients within a year if no maintenance treatment is taken. Hence, Vraylar's label expansion as a maintenance therapy will cater to the hugely unmet need of patients, requiring a long-term treatment option for the disease.

Other players in the bipolar disorder and schizophrenia treatment market are AstraZeneca plc's AZN Seroquel XR, Johnson & Johnson's JNJ Risperdal Consta and Alkermes plc's ALKS Aristada.

Allergan PLC. Price

Allergan PLC. Price | Allergan PLC. Quote

Zacks Rank

Allergan carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Astrazeneca PLC (AZN): Free Stock Analysis Report

Allergan PLC. (AGN): Free Stock Analysis Report

Johnson & Johnson (JNJ): Free Stock Analysis Report

Alkermes PLC (ALKS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Business , Stocks
Referenced Symbols: AZN , AGN , JNJ , ALKS


More from Zacks.com

Subscribe






Zacks.com
Contributor:

Zacks.com

Equity Research








Research Brokers before you trade

Want to trade FX?





Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com